Please login to the form below

Not currently logged in
Email:
Password:

Eisai moves to end Aricept partnership

Eisai claims that it has the right to terminate the strategic alliance and development agreement with Pfizer for Aricept after the pharma giant's buyout of Wyeth

Eisai claims that it has the right to terminate the strategic alliance and development agreement with Pfizer for Aricept after the pharma giant's buyout of Wyeth. A tug of war is likely to ensue with Pfizer already denying that the Japanese drugmaker has any basis for this challenge.

The bone of contention and trigger for Eisai's claim appears to be Wyeth's in-pipeline Alzheimer's medications. When Pfizer announced its $68bn Wyeth buyout, it made an offhand reference to potential trouble with Eisai. This is the first real indication that the Japanese company wants out of the deal.

Aricept added $482m to Pfizer's top line in 2008, and the drug accounted for 38 per cent of Eisai's sales for the nine months ending December 31, 2008.

11th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics